Dynamic Area Telethermometry (DAT) as an Imaging Modality in Patients With Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00165100|
Recruitment Status : Completed
First Posted : September 14, 2005
Last Update Posted : December 28, 2007
|Condition or disease||Intervention/treatment||Phase|
|Malignant Tumors Subcutaneous Tumors Lymph Node Tumors||Procedure: Dynamic Area Telethermometry (DAT)||Not Applicable|
- The DAT system resembles a video camera which picks up changes in body temperature which may reflect disease-related changes in blood flow to some areas, particularly those involved with tumors.
- Patients with known tumor sites amendable to DAT evaluation will be imaged at the time of staging and at later time points. Thermal profiles will be compared to those of normal adjacent tissues and correlated with the images of the tumors on conventional images.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Dynamic Area Telethermometry (DAT) as an Auxiliary Imaging Modality in Assessment of Patients With Cancer|
|Study Start Date :||January 2000|
|Actual Primary Completion Date :||October 2002|
|Actual Study Completion Date :||October 2002|
- To assess the feasibility of DAT in tumors detected by conventional imaging and evaluation of therapy induced changes in DAT imaging profile over time.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00165100
|United States, Massachusetts|
|Dana-Farber Cancer Institute|
|Boston, Massachusetts, United States, 02115|
|Principal Investigator:||Milos Janicek, MD, PhD||Dana-Farber Cancer Institute|